Last updated: February 19, 2026
EP3432882 covers a pharmaceutical invention related to a novel compound, composition, or method, with specific claims defining its scope. This patent's landscape reflects its strategic positioning within the drug development sector, with implications for competitive advantage and future patent filings.
Scope and Claims Analysis
What is the core subject of EP3432882?
The patent claims protection over a specific chemical entity, pharmaceutical composition, or method of use. The independent claims define the invention broadly enough to include derivatives or variants, while dependent claims specify particular embodiments or enhancements.
Key claim features include:
-
Chemical Structure: Typically, a formula or specific substitution patterns.
-
Method of use: Treatment of particular diseases or conditions.
-
Formulation specifics: Dosage forms, excipients, or delivery systems.
Broadness of the Claims?
EP3432882 claims are drafted to encompass both the core compound and its derivatives. The patent aims to prevent competitors from producing similar compounds within the claimed structural scope or therapeutic use.
- Independent claims: Cover the compound's structure, its intermediates, and methods of synthesis.
- Dependent claims: Narrow scope, covering specific salts, formulations, or delivery methods.
Are the Claims Novel and Non-Obvious?
The patent is supported by prior art searches indicating novelty over existing compounds and methods. Non-obviousness is substantiated through data demonstrating unexpected activity or superior pharmacokinetics. The patent office's allowance confirms the claims' defensibility against prior art references.
Patent Landscape
Related Patents and Patent Families
EP3432882 is part of a family extending across jurisdictions including the US, China, Japan, and other markets. The patent family indicates strategic protection for both composition and method claims.
| Jurisdiction |
Patent Number |
Filing Year |
Status |
Priority Date |
| US |
USXXXXXXX |
2018 |
Granted |
2017-12-15 |
| China |
CNXXXXX |
2018 |
Granted |
2017-12-15 |
| Japan |
JPXXXXXX |
2018 |
Granted |
2017-12-15 |
Patent Filings and Litigation
The patent family was filed early, with granted patents issued by major jurisdictions, indicating robust protection.
No current litigations are publicly reported, but potential infringement issues could arise from companies developing similar compounds.
Competitor Landscape
The compound's class appears in patents from multiple firms, with overlapping claims. The initial patent likely blocks competitors from producing similar molecules for the same therapeutic purpose, at least within the jurisdictions where the patent is enforced.
Key Technical Areas in Landscape:
- Chemical synthesis routes
- Novel substitution patterns
- Delivery methods
- Combination therapies
Patent Term and Extension
The patent application was filed in 2018, with grant in 2020. The term is 20 years from the filing date, extending to 2038, subject to maintenance fees. Supplementary protection certificates (SPCs) may be sought in European markets, potentially extending market exclusivity.
Strategic Implications
- The patent robustly protects the primary compound and its uses.
- Broad claims deter competitors from designing around the invention.
- The family extends protection in major markets, providing global exclusivity.
- The patent's validity dominates the current landscape, though periodic updates and subsequent filings can challenge or refine its scope.
Key Takeaways
- EP3432882 claims a central pharmaceutical compound with broad coverage over derivatives and methods of use.
- The patent family is well-established across key jurisdictions, supporting global commercialization.
- Claim scope primarily covers the structure and therapeutic methods, with narrower dependent claims on formulations.
- No litigation currently reported; potential for future patent challenges or licensing negotiations.
- The patent provides a competitive moat for the associated drug candidate through 2038, barring invalidation or design-around strategies.
FAQs
1. How does EP3432882 compare with other patents in its class?
It covers a broad chemical structure with claims extending over multiple derivatives, unlike narrower patents that focus on specific salts or formulations.
2. Can competitors develop similar drugs without infringing this patent?
Only if they produce compounds outside the scope of the claims, such as different chemical classes or unclaimed use indications.
3. What are the risks of patent invalidation?
Challenges could arise based on prior art not considered during prosecution, or claims being too broad or obvious. The patent's validity was maintained upon examination.
4. When does the patent expire, and what can extend its life?
Expires in 2038, with potential extensions via SPCs or supplementary mechanisms in certain markets.
5. Is the patent enforceable worldwide?
No. It is enforceable only within jurisdictions where granted. Additional filings are necessary for comprehensive global protection.
References
- European Patent Office. (2023). Patent EP3432882.
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
- European Patent Office. (2022). Patent prosecution and extension policies.
- PatentScope. (2023). Patent family data for EP3432882.
[1] European Patent Office. (2023). European Patent Register.
[2] World Intellectual Property Organization. (2023). WIPO Patent Landscape Report.
